Matinas BioPharma Holdings Inc (MTNB) Sees Significant Increase in Short Interest

Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) was the target of a significant growth in short interest in December. As of December 31st, there was short interest totalling 4,100,334 shares, a growth of 6.8% from the December 14th total of 3,839,495 shares. Currently, 4.4% of the shares of the stock are sold short. Based on an average daily volume of 923,214 shares, the days-to-cover ratio is currently 4.4 days.

Separately, Maxim Group raised their target price on shares of Matinas BioPharma from $2.00 to $5.00 and gave the company a “buy” rating in a research note on Monday, November 12th.

Shares of NYSEAMERICAN MTNB opened at $0.87 on Friday. Matinas BioPharma has a one year low of $0.32 and a one year high of $1.48.

Matinas BioPharma (NYSEAMERICAN:MTNB) last issued its quarterly earnings results on Monday, November 12th. The company reported ($0.03) EPS for the quarter.

Hedge funds and other institutional investors have recently modified their holdings of the business. Renaissance Technologies LLC grew its position in Matinas BioPharma by 325.6% during the third quarter. Renaissance Technologies LLC now owns 134,900 shares of the company’s stock valued at $124,000 after acquiring an additional 103,200 shares during the last quarter. K.J. Harrison & Partners Inc bought a new position in Matinas BioPharma during the third quarter valued at approximately $150,000. Finally, Paloma Partners Management Co grew its position in Matinas BioPharma by 1,724.7% during the second quarter. Paloma Partners Management Co now owns 317,499 shares of the company’s stock valued at $138,000 after acquiring an additional 300,099 shares during the last quarter.

TRADEMARK VIOLATION NOTICE: “Matinas BioPharma Holdings Inc (MTNB) Sees Significant Increase in Short Interest” was reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The original version of this piece of content can be accessed at

About Matinas BioPharma

Matinas BioPharma Holdings, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. The company enables the delivery of life-changing medicines using its lipid nano-crystal (LNC) platform technology. Its LNC delivery technology platform utilizes lipid nano-crystals which can encapsulate small molecules, oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable.

See Also: Short Selling Stocks, A Beginner’s Guide

Receive News & Ratings for Matinas BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas BioPharma and related companies with's FREE daily email newsletter.

Leave a Reply